ArticleHematology. American Society of Hematology. Education Program2023

The future paradigm of HMA + VEN or targeted inhibitor approaches: sequencing or triplet combinations in AML therapy.

Sangeetha Venugopal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.